left-arrow right-arrow pinterest facebook google_plus linkedin

Gynecology Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


GOG-0238

Radiation Therapy With or Without Cisplatin in Treating Patients with Recurrent Endometrial Cancer

Status: Recruiting | Phase II

Official Title: A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus

Study Purpose: To determine if adding chemotherapy to radiation therapy is better than radiation therapy alone to treat patients with endometrial cancer that has come back. Learn more


GOG-0263

Radiation Therapy With or Without Chemotherapy In Patients with Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Status: Recruiting | Phase III

Official Title: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Study Purpose: To determine if adding chemotherapy to radiation therapy (CRT) can prevent or lengthen the time to recurrence when compared to radiation therapy (RT) alone. Learn more.


GOG-3029/ENGOT-0v50/INNOVATE-3, EF-28

Status: Recruiting | Phase III

Official Title: Pivotal, Randomized, Open-Label Study Of Tumor Treating Fields (TTFields, 200khz) Concomitant With Weekly Paclitaxel For The Treatment Of Recurrent Ovarian Cancer

Study Purpose: To compare treatment using TTFields together with standard of care chemotherapy (called Paclitaxel) to standard of care chemotherapy (Paclitaxel) without TTFields. This study will help determine if using TTFields with chemotherapy is better than the usual approach of chemotherapy alone.  Learn more.


NRG GY005

Status: Recruiting | Phase III

Official Title: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Study Purpose: To confirm the effectiveness of the combination of Cediranib and Olaparib to the standard chemotherapy. Learn more


NRG GY009

Status: Suspended | Phase III

Official Title: A Randomized, Phase II/III Study Of Pegylated Liposomal Doxorubicin And Ctep-Supplied Atezolizumab (Ind #134427) Versus Pegylated Liposomal Doxorubicin/Bevacizumab And Ctep-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab In Platinum Resistant Ovarian Cancer

Study Purpose: The purpose of this study is to compare any good and bad effects of adding Atezolizumab to the usual chemotherapy, (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab. Learn more


NRG GY014

Status: Suspended | Phase II 

Official Title: A phase II study of tazemetostat (EPZ-6438) (IND#138671) in recurrent or persistent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma

Study Purpose: To find out if this approach is better or worse than the usual approach for your ovarian or endometrial cancer. Learn more


NRG GY016

Status: Suspended | Phase II

Official Title: Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Study Purpose: To test any good and bad effects of the combination of two study drugs called MK-3475 (Pembrolizuma b) and Epacadostat in treatment of clear cell ovarian cancer. Learn more


NRG GY018

Status: Suspended | Phase III

Official Title: Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Endometrial Cancer.

Study Purpose: The purpose of this study is to compare any good and bad effects of adding immunotherapy drugs to the usual combination of chemotherapy drugs. Learn more


NRG GY019

Status: Recruiting | Phase III

Official Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Study Purpose: To determine how well the oral drug Letrozole works with or without Paclitaxel and Carboplatin in treating stage II-IV low grade cancer of the ovary or peritoneum. Learn more


RTOG-0724

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy.

Status: Recruiting | Phase III 

Official Title: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Study Purpose: To determine if adding chemotherapy after the usual treatment of chemotherapy and radiation therapy will prevent or lengthen the time to recurrence when compared to the usual treatment of chemotherapy and radiation therapy alone. Learn more.


Merck MK7339-001/GOG-3036

Status: Recruiting | Phase III 

Official Title: First-Line Chemotherapy Plus Pembrolizumab and Olaparib for BRCA Non-Mutated Advanced Epithelial Ovarian Cancer (EOC)

Study Purpose: To test the safety of the study drug, pembrolizumab (MK- 3475) with chemotherapy followed by olaparib OR pembrolizumab with chemotherapy compared to chemotherapy alone to see how well the drugs work and to see how your body handles them.  Learn more.


InterVenn OVACA-001

Status: Recruiting | Phase: Not Applicable

Official Title: Clinical Validation of the InterVenn Ovarian Cancer Liquid Biopsy: VOCAL Study

Study Purpose: To evaluate the clinical performance for the InterVenn Ovarian Cancer Liquid Biopsy by collecting and storing blood samples and characterizing protein biomarkers in the blood of cancer vs. non-cancer patients.  Learn more.